RTP Mobile Logo

Sunday, March 29, 2020, Toronto, Canada, 12:00 PM – 1:30 PM

Beyond the Guidelines: Clinical Investigator Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Update regarding COVID-19

The Society of Gynecologic Oncology (SGO) has announced it will not conduct its 2020 Annual Meeting on Women’s Cancer, March 28-31, in Toronto, Ontario, Canada. SGO is exploring alternatives for delivering the scientific and educational sessions, so please check back here for more updates on our satellite symposia. For up-to-date information on Research To Practice’s live events, please sign up for our email alerts.

Last updated 3/9/2020

Event Details

Metro Toronto Convention Centre
222 Bremner Blvd
Toronto, ON M5V 3L9

11:30 AM – 12:00 PM — Registration and Lunch Buffet
12:00 PM – 1:30 PM — Educational Meeting

Meeting Room
Room 718 (Level 700 – South Building)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Robert L Coleman, MD
Professor and Executive Director
Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Professor Ignace Vergote
Chairman, Department of Obstetrics and Gynaecology
Gynaecological Oncologist
Leuven Cancer Institute
University Hospital Leuven
Leuven, Belgium

Additional faculty to be announced

Neil Love, MD
Research To Practice
Miami, Florida


This CME symposium will focus on the burgeoning role of PARP inhibition in the management of ovarian cancer (OC). Research To Practice (RTP) president and medical oncologist Dr Neil Love will moderate the program, and 4 clinical investigators will serve as the faculty. Leading up to the event, RTP will recruit 21 additional medical and gynecologic oncology investigators who, along with the faculty, will participate in a unique educational survey designed to illuminate their general practice patterns regarding the protocol and nonprotocol role of PARP inhibitors in the treatment of patients with OC. RTP will aggregate the results of the assessment and prioritize key data points for presentation during the program. The activity will be divided into four distinct modules, each featuring graphical displays of the investigator survey results and a faculty member-led review of relevant research and ongoing clinical trials. To make the program more interactive and relevant to those in the room, clinician attendees will use networked iPads® to complete a similar survey, the results of which will be juxtaposed with those of the investigators to illuminate knowledge and practice gaps among the community practitioners. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge. A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Recognize the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer harboring a deleterious or suspected deleterious BRCA germline or somatic mutation and appropriately integrate this agent into the current care of these individuals.
  • Review emerging trial data evaluating the use of niraparib as maintenance therapy in the first-line setting for patients with or without BRCA mutations and consider the potential clinical and research implications of these findings.
  • Appreciate the biologic rationale for and available data with the use of PARP inhibitors in combination with antiangiogenic agents or chemotherapy and discern how these therapeutic approaches may affect treatment algorithms in the future.
  • Assess available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory ovarian cancer in order to design personalized care plans potentially incorporating these agents.
  • Develop an understanding of the rationale for, available data with and ongoing research efforts evaluating PARP inhibitors in combination with immunotherapy or other targeted therapies in order to counsel appropriately selected patients about clinical trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck and Tesaro, A GSK Company.


Metro Toronto Convention Centre
222 Bremner Blvd
Toronto, ON M5V 3L9

Meeting Room
Room 718 (Level 700 – South Building)

The Metro Toronto Convention Centre is the main venue for the SGO Annual Meeting on Women’s Cancer.


This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.